Table 3.
Follow up data of the patients of the study group
| Study group | p Value* | |
| VA at baseline (n = 97) | ||
| LogMar | 0.98 (0.36) | |
| Snellen lines | 13.3 (3.2) | |
| Snellen acuity | 0.14 (0.10) | |
| VA after 1 week (n = 57) | ||
| LogMar units | 0.86 (0.32) | 0.001 |
| Snellen lines | 14.4 (3.2) | 0.001 |
| Snellen acuity | 0.18 (0.15) | 0.002 |
| VA after 1 month (n = 64) | ||
| LogMar units | 0.83 (0.37) | <0.001 |
| Snellen lines | 14.7 (3.7) | <0.001 |
| Snellen acuity | 0.20 (0.14) | <0.001 |
| VA after 2 months (n = 52) | ||
| LogMar units | 0.81 (0.33) | <0.001 |
| Snellen lines | 14.8 (3.3) | <0.001 |
| Snellen acuity | 0.20 (0.14) | <0.001 |
| VA after 3 months (n = 51) | ||
| LogMar units | 0.81 (0.34) | <0.001 |
| Snellen lines | 15.0 (3.4) | <0.001 |
| Snellen acuity | 0.20 (0.14) | <0.001 |
| VA after 4 months (n = 37) | ||
| LogMar units | 0.78 (0.46) | <0.001 |
| Snellen lines | 15.4 (4.2) | 0.001 |
| Snellen acuity | 0.25 (0.18) | <0.001 |
| VA after 5 months (n = 29) | ||
| LogMar units | 0.86 (0.31) | 0.034 |
| Snellen lines | 14.5 (3.0) | 0.046 |
| Snellen acuity | 0.18 (0.13) | 0.021 |
| VA after 6 months (n = 25) | ||
| LogMar units | 0.86 (0.33) | 0.033 |
| Snellen lines | 14.2 (3.36) | 0.099 (NS) |
| Snellen acuity | 0.18 (0.13) | 0.068 (NS) |
| VA after 7 months (n = 18) | ||
| LogMar units | 0.89 (0.59) | 0.042 |
| Snellen lines | 14.6 (4.3) | 0.020 (NS) |
| Snellen acuity | 0.19 (0.12) | 0.006 |
| VA after 8 months (n = 20) | ||
| LogMar units | 0.83 (0.31) | 0.17 (NS) |
| Snellen lines | 14.7 (3.1) | 0.17 (NS) |
| Snellen acuity | 0.19 (0.13) | 0.18 (NS) |
| VA after 9 months (n = 16) | ||
| LogMar units | 0.92 (0.43) | 0.22 (NS) |
| Snellen lines | 13.9 (4.3) | 0.19 (NS) |
| Snellen acuity | 0.19 (0.18) | 0.068 (NS) |
| VA after 10 months (n = 9) | ||
| LogMar units | 0.92 (0.43) | 0.22 (NS) |
| Snellen lines | 13.4 (3.8) | 0.93 (NS) |
| Snellen acuity | 0.15 (0.11) | 0.87 (NS) |
| VA after 11 months (n = 9) | ||
| LogMar units | 1.03 (0.41) | 0.27 (NS) |
| Snellen lines | 12.8 (4.1) | 0.27 (NS) |
| Snellen acuity | 0.14 (0.14) | 0.27 (NS) |
| VA after 12 months (n = 9) | ||
| LogMar units | 0.90 (0.30) | 0.55 (NS) |
| Snellen lines | 14.0 (3.0) | 0.55 (NS) |
| Snellen acuity | 0.16 (0.12) | 0.40 (NS) |
| VA after 13 months (n = 4) | ||
| LogMar units | 0.90 (0.38) | 1.00 (NS) |
| Snellen lines | 14.0 (3.9) | 0.79 (NS) |
| Snellen acuity | 0.16 (0.11) | 0.59 (NS) |
| VA after 14 months (n = 4) | ||
| LogMar units | 1.21 (0.14) | 0.46 (NS) |
| Snellen lines | 11.0 (1.4) | 0.46 (NS) |
| Snellen acuity | 0.07 (0.02) | 0.47 (NS) |
| VA after 15 months (n = 10) | ||
| LogMar units | 1.01 (0.29) | 0.24 (NS) |
| Snellen lines | 13.0 (2.9) | 0.33 (NS) |
| Snellen acuity | 0.12 (0.08) | 0.18 (NS) |
*Statistical significance of difference between baseline and follow up data.
NS, statistically not significant. Results presented as mean (standard deviation).